JAMES R DASCH
Broker in Needham, MA
License number
Massachusetts 9067380
Issued Date
Jul 6, 2004
Expiration Date
Feb 17, 2007
Type
Salesperson
Address
Address
Needham, MA 02494
Professional information
Method Of Modifying The Release Profile Of Sustained Release Compositions
US Patent:
6558702, May 6, 2003
Filed:
Apr 13, 2001
Appl. No.:
09/835001
Inventors:
James R. Dasch - Needham MA
M. Gary I. Riley - Cambridge MA
M. Gary I. Riley - Cambridge MA
Assignee:
Alkermes Controlled Therapeutics, Inc. - Cambridge MA
International Classification:
A61K 914
US Classification:
424484, 424422, 424423, 424486, 424489, 424499, 424501, 514 2, 514 21, 514 44, 514 89, 514107, 514108, 514964
Abstract:
The present invention relates to a method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active agent incorporated therein, and a bisphosphonate wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.
Method Of Modifying The Release Profile Of Sustained Release Compositions
US Patent:
2004012, Jun 24, 2004
Filed:
Oct 8, 2003
Appl. No.:
10/681571
Inventors:
James Dasch - Needham MA, US
M. Gary Riley - Boston MA, US
Paul Burke - Oxnard CA, US
Stephen Zale - Hopkinton MA, US
M. Gary Riley - Boston MA, US
Paul Burke - Oxnard CA, US
Stephen Zale - Hopkinton MA, US
Assignee:
Alkermes Controlled Therapeutics, Inc. - Cambridge MA
International Classification:
A61K031/573, A61K009/22
US Classification:
424/468000, 514/179000
Abstract:
The present invention relates to a method for the sustained release in vivo of a biologically active labile agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active labile agent incorporated therein, and a corticosteroid wherein the labile is released for a period of at least about two weeks. It is understood that the corticosteroid is present in an amount sufficient to modify the release profile of the biologically active labile agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.
Systems And Methods For Quantitative Analyte Transfer
US Patent:
2010003, Feb 11, 2010
Filed:
Aug 7, 2008
Appl. No.:
12/188119
Inventors:
Malcolm G. Pluskal - Acton MA, US
Tom Miller - East Boston MA, US
James Dasch - Needham MA, US
Tom Miller - East Boston MA, US
James Dasch - Needham MA, US
International Classification:
G01N 27/447, B32B 3/26
US Classification:
204601, 4283166, 204451, 204456, 204605
Abstract:
Systems and methods for enhancing quantitative transfer of analytes to an adsorptive substrate are provided. A preferred embodiment provides an improved transfer system and method that reduces “blow through” of low molecular weight analytes and increases the adsorption of low molecular weight, for example proteins of about 30 kDa or less compared to conventional transfer techniques. It has been discovered that using a secondary porous backing membrane in conjunction with an adsorptive membrane such as nitrocellulose or polvinylidene fluoride increases the efficiency of analyte interaction with the adsorption membrane compared to transfers techniques using the adsorption membrane without the secondary backing membrane. This improvement of quantitative analyte transfer efficiency facilitates a wider range of detection processes, such as direct analysis by MALDI mass spectrometry than in earlier applications of the process without the secondary backing membrane.
Mass Spectrometer Output Analysis Tool For Identification Of Proteins
US Patent:
2010028, Nov 4, 2010
Filed:
May 27, 2009
Appl. No.:
12/473005
Inventors:
Oren Kagan - Chestnut Hill MA, US
James R. Dasch - Needham MA, US
Aaron Sin - St. Louis MO, US
James R. Dasch - Needham MA, US
Aaron Sin - St. Louis MO, US
Assignee:
Cell Biosciences - San Leandro CA
International Classification:
G06F 19/00, G01N 33/68
US Classification:
702 19
Abstract:
Methods and apparatus for consolidation and visualization of a dataset output from a mass spectrometer. The number of proteins identified in a mass spectrometry experiment may be systematically reduced by identifying and excluding proteins which may not be necessary to explain the observed peptides in a sample. Peptide counts from excluded proteins may be redistributed to non-excluded proteins to preserve total observed peptide counts. The consolidated dataset may be represented as a data structure having a plurality of cells arranged into rows and columns. Visual parameter values may be assigned to various cells in the data structure to emphasize particular features of the data. Data from multiple samples may be arranged in sets of columns in the data structure, and difference scores may be calculated to determine peptide expression differences between the multiples samples. The difference scores may be displayed using textual and/or graphical representations to facilitate data analysis.
Monoclonal Antibodies To Tgf-Beta
US Patent:
2002017, Nov 28, 2002
Filed:
Jun 17, 2002
Appl. No.:
10/173074
Inventors:
James Dasch - Needham MA, US
Doran Pace - San Francisco CA, US
Wendy Waegell - Worcester MA, US
Doran Pace - San Francisco CA, US
Wendy Waegell - Worcester MA, US
International Classification:
A61K039/395, C12N005/06, C07K016/22
US Classification:
424/145100, 530/388240, 435/336000
Abstract:
Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF-B monoclonal antibody are also disclosed.
Method Of Modifying The Release Profile Of Sustained Release Compositions
US Patent:
7074432, Jul 11, 2006
Filed:
Jan 16, 2004
Appl. No.:
10/758717
Inventors:
James R. Dasch - Needham MA, US
M. Gary I. Riley - Cambridge MA, US
M. Gary I. Riley - Cambridge MA, US
Assignee:
Alkermes Controlled Therapeutics, Inc. - Cambridge MA
International Classification:
A61K 9/14, A61K 9/52
US Classification:
424486, 424422, 424501, 514964
Abstract:
The present invention relates to a method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active agent incorporated therein, and a bisphosphonate wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.
Method Of Modifying The Release Profile Of Sustained Release Compositions
US Patent:
2003023, Dec 25, 2003
Filed:
Mar 25, 2003
Appl. No.:
10/400162
Inventors:
James Dasch - Needham MA, US
M. I. Riley - Cambridge MA, US
M. I. Riley - Cambridge MA, US
Assignee:
Alkermes Controlled Therapeutics, Inc. - Cambridge MA
International Classification:
A61K038/00
US Classification:
514/012000
Abstract:
The present invention relates to a method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active agent incorporated therein, and a bisphosphonate wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.
Method Of Modifying The Release Profile Of Sustained Release Compositions
US Patent:
2006026, Nov 30, 2006
Filed:
May 8, 2006
Appl. No.:
11/429930
Inventors:
James Dasch - Needham MA, US
M. Riley - Cambridge MA, US
M. Riley - Cambridge MA, US
International Classification:
A61K 31/675, A61K 9/22, A61K 31/663
US Classification:
424468000, 514089000, 514102000
Abstract:
The present invention relates to a method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active agent incorporated therein, and a bisphosphonate wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.
Method Of Modifying The Release Profile Of Sustained Release Compositions
US Patent:
2008005, Mar 6, 2008
Filed:
Jul 17, 2007
Appl. No.:
11/826694
Inventors:
James Dasch - Needham MA, US
M. Gary Riley - Boston MA, US
Paul Burke - Oxnard CA, US
Stephen Zale - Hopkinton MA, US
M. Gary Riley - Boston MA, US
Paul Burke - Oxnard CA, US
Stephen Zale - Hopkinton MA, US
Assignee:
Alkermes Controlled Therapeutics, Inc. - Cambridge MA
International Classification:
A61K 38/02, A61K 9/00, A61P 43/00
US Classification:
424499000, 514002000
Abstract:
The present invention relates to a method for the sustained release in vivo of a biologically active labile agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active labile agent incorporated therein, and a corticosteroid wherein the labile is released for a period of at least about two weeks. It is understood that the corticosteroid is present in an amount sufficient to modify the release profile of the biologically active labile agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.
Microencapsulation And Sustained Release Of Biologically Active Polypeptides
US Patent:
8129339, Mar 6, 2012
Filed:
Nov 6, 2008
Appl. No.:
12/289857
Inventors:
Henry R. Costantino - Woodinville WA, US
Joyce M. Hotz - Cincinnati OH, US
James R. Dasch - Needham MA, US
M. Gary I. Riley - Boston MA, US
Paul A. Burke - Philadelphia PA, US
Stephen E. Zale - Hopkinton MA, US
Joyce M. Hotz - Cincinnati OH, US
James R. Dasch - Needham MA, US
M. Gary I. Riley - Boston MA, US
Paul A. Burke - Philadelphia PA, US
Stephen E. Zale - Hopkinton MA, US
Assignee:
Alkermes Pharma Ireland Limited - Athlone
International Classification:
A61K 38/00, A61K 38/28, A61P 5/50, A61P 3/08, A61P 3/10, A61P 7/12
US Classification:
514 67, 514 68, 514 69
Abstract:
The invention relates to compositions and methods for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein a biologically active polypeptide, and a corticosteroid to modify the release profile and provide increased bioavailability.